Comparison 13. Anti‐PD1 monoclonal antibodies versus anti‐CTLA4 monoclonal antibodies.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
13.1 Overall survival	1	834	Hazard Ratio (IV, Random, 95% CI)	0.63 [0.60, 0.66]
13.2 Progression‐free survival	2	1465	Hazard Ratio (IV, Random, 95% CI)	0.54 [0.50, 0.60]
13.3 Tumour response	2	1465	Risk Ratio (M‐H, Random, 95% CI)	2.47 [2.01, 3.04]
13.4 Toxicity (≥ G3)	2	1435	Risk Ratio (M‐H, Random, 95% CI)	0.70 [0.54, 0.91]